Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Meets high risk or at potential risk for tumor lysis syndrome (TLS):~   A patient is at high risk for TLS if he/she presents with:~  * Hyperuricemia of malignancy (plasma uric acid \> 7.5 mg/dL);~  * A diagnosis of very aggressive lymphoma/leukemia based on the Revised European-American Lymphoma (REAL) classification of lymphoma/leukemia;~  * Acute myeloid leukemia (AML);~  * Chronic myeloid leukemia (CML) in blast crisis; or~  * High grade myelodysplastic syndrome (refractory anemia with excess blast, chronic myelomonocytic leukemia, and refractory anemia with excess blast in transformation) only if they have \> 10% bone marrow blast involvement and are given aggressive treatment similar to AML.~   A patient is at potential risk for TLS if he/she presents with:~  * A diagnosis of aggressive lymphoma/leukemia based on the REAL classification of lymphoma/leukemia plus 1 or more of the following criteria:~     * Lactate dehydrogenase (LDH) \>= 2 x upper limit of normal (ULN) (IU/L)~    * Stage III-IV disease~    * Stage I-II disease with at least 1 lymph node/tumor \> 5 cm in diameter~   In addition to the above-mentioned eligibility criteria, the patients should have the following criteria:~2. Eastern Cooperative Oncology Group (ECOG) performance status 0-3~3. Age \>= 18 years~4. Life expectancy \> 3 months~5. Negative pregnancy test (females of child bearing potential) and use of effective contraceptive method (for both males and females). A pregnancy test may be performed on serum or urine human chorionic gonadotropin (HCG).~6. Signed written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Rasburicase alone given as a single agent for 5 days
- Arm B (Type: EXPERIMENTAL): Rasburicase alone given as a single agent from Day 1 through Day 3, followed by oral allopurinol given from Day 3 through Day 5 (Day 3 is an overlap)
- Arm C (Type: ACTIVE_COMPARATOR): Oral allopurinol alone given as a single agent for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).